文献速递浆细胞疾病

KTd与自体干细胞移植应答适应性挽救治疗功能性高危多发性骨髓瘤——澳大利亚白血病与淋巴瘤工作组(ALLG)MM17试验

Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
PubMed 文献 · Br J Haematol · 2023-06-18

本研究评估卡非佐米-沙利度胺-地塞米松(KTd)再诱导联合自体干细胞移植(ASCT)用于新诊断多发性骨髓瘤(NDMM)对非IMID硼替佐米诱导难治或应答欠佳者。共入组50例,ASCT前KTd总缓解率(ORR)78%,ASCT后12个月意向治疗人群EuroFlow微小残留病(MRD)阴性率34%、可评估人群65%。中位随访>38个月,中位PFS和OS未达到,36个月PFS和OS分别为64%和80%。

要点

  • KTd挽救方案用于硼替佐米诱导难治或应答欠佳的NDMM,ASCT前ORR达78%。
  • ASCT后12个月EuroFlow MRD阴性率在意向治疗人群为34%、可评估人群为65%。
  • 中位随访>38个月,36个月PFS和OS分别为64%和80%,中位PFS和OS未达到。

核心结论

  • KTd应答适应性联合ASCT在功能性高危NDMM中与高质量缓解和持久疾病控制相关。

研究设计与样本

  • 评估KTd再诱导联合ASCT用于对非IMID硼替佐米诱导难治或应答欠佳的NDMM。
  • 共入组50例患者。
  • 主要终点为ASCT前KTd的总缓解率(ORR)。

主要发现

  • ASCT前KTd的ORR为78%。
  • ASCT后12个月EuroFlow MRD阴性率在意向治疗人群为34%、在可评估人群为65%。
  • 中位随访>38个月,中位PFS和OS未达到,36个月PFS和OS分别为64%和80%。
  • KTd耐受良好,3级和≥4级不良事件发生率分别为32%和10%。

关键数值与推荐

  • KTd方案:沙利度胺100 mg每日口服、地塞米松20 mg口服,联合卡非佐米56 mg/m²,每个28天周期第1、2、8、9、15、16天给药。
  • 4周期后达到严格完全缓解者进入ASCT,未达到者再接受2周期后行ASCT。
  • 巩固治疗为2周期KTd后Td,至ASCT后总治疗12个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated re-induction incorporating carfilzomib-thalidomide-dexamethasone (KTd) and autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (NDMM) refractory, or demonstrating a suboptimal response, to non-IMID bortezomib-based induction. KTd salvage consisted of thalidomide 100 mg daily and dexamethasone 20 mg orally combined with carfilzomib 56 mg/m2 days 1, 2, 8, 9, 15 and 16, of each 28-day cycle. Following four cycles, patients achieving a stringent complete response proceeded to ASCT whereas those who did not received a further two cycles then ASCT. Consolidation consisted of two cycles of KTd then Td to a total of 12 months post-ASCT therapy. Primary end-point was the overall response rate (ORR) with KTd prior to ASCT. Fifty patients were recruited. The ORR was 78% with EuroFlow MRD negativity of 34% in the intention-to-treat population and 65% in the evaluable population at 12 months post-ASCT. With follow-up >38 months median PFS and OS have not been reached with PFS and OS at 36 months of 64% and 80%, respectively. KTd was well tolerated with grade 3 and grade ≥4 adverse events rates of 32% and 10%, respectively. Response adaptive utilisation of KTd with ASCT is associated with both high-quality responses and durable disease control in functional high-risk NDMM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Turner R, Quach H, Horvath N, et al. Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial. Br J Haematol. 2023. PMID: 37332079. doi:10.1111/bjh.18914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。